SARS ‐ CoV ‐2 antibody levels and long COVID occurrence in blood donors

作者：Vivian Iida Avelino‐Silva, Roberta Bruhn, Karla G. Zurita, Xutao Deng, Elaine A. Yu, Eduard Grebe, Mars Stone, Marion C. Lanteri, Bryan R. Spencer, Michael P. Busch, Brian Custer · 发表于：Transfusion · 年份：2024 · DOI：10.1111/trf.17952 · 被引用次数：4 · 研究领域：Long-Term Effects of COVID-19、Olfactory and Sensory Function Studies、Respiratory and Cough-Related Research

BACKGROUND: Long COVID is a common condition lacking consensus definition; determinants remain incompletely understood. Characterizing immune profiles associated with long COVID could support the development of preventive and therapeutic strategies. METHODS: We used a survey to investigate blood donors' infection/vaccination history and acute/persistent symptoms following COVID-19. The prevalence of long COVID was evaluated using self-report and an adapted definition from the RECOVER study. We evaluated factors associated with long COVID, focusing on anti-spike and anti-nucleocapsid SARS-CoV-2 antibodies. Lastly, we investigated long COVID clinical subphenotypes using hierarchical clustering. RESULTS: Of 33,610 participants, 16,003 (48%) reported having had COVID-19; 1853 (12%) had self-reported long COVID, 685 (4%) met an adapted RECOVER definition, and 2050 (13%) met at least one definition. Higher anti-nucleocapsid levels measured 12-24 weeks post-infection were associated with higher risk of self-reported and RECOVER long COVID. Higher anti-spike IgG levels measured 12-24 weeks post-infection were associated with lower risk of self-reported long COVID. Higher total anti-spike measured 24-48 weeks post-infection was associated with lower risk of RECOVER long COVID. Cluster analysis identified four clinical subphenotypes; patterns included neurological and psychiatric for cluster 1; neurological and respiratory for cluster 2; multi-systemic for cluster 3; and neurological f...